These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38804723)

  • 1. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
    Haddad FG; Sasaki K; Nasr L; Short NJ; Kadia T; Dellasala S; Cortes J; Nicolini FE; Issa GC; Jabbour E; Kantarjian H
    Cancer; 2024 Oct; 130(19):3344-3352. PubMed ID: 38804723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
    Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
    Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
    Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
    Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Jabbour E; Kantarjian HM; Aldoss I; Montesinos P; Leonard JT; Gómez-Almaguer D; Baer MR; Gambacorti-Passerini C; McCloskey J; Minami Y; Papayannidis C; Rocha V; Rousselot P; Vachhani P; Wang ES; Wang B; Hennessy M; Vorog A; Patel N; Yeh T; Ribera JM
    JAMA; 2024 Jun; 331(21):1814-1823. PubMed ID: 38722621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
    Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre P; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DiPersio J; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Rivera VM; Clackson T; Turner CD; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes T; Goldman JM; Shah NP; Kantarjian H;
    N Engl J Med; 2013 Nov; 369(19):1783-96. PubMed ID: 24180494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ponatinib in refractory Philadelphia chromosome-positive leukemias.
    Cortes JE; Kantarjian H; Shah NP; Bixby D; Mauro MJ; Flinn I; O'Hare T; Hu S; Narasimhan NI; Rivera VM; Clackson T; Turner CD; Haluska FG; Druker BJ; Deininger MW; Talpaz M
    N Engl J Med; 2012 Nov; 367(22):2075-88. PubMed ID: 23190221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.
    Jain P; Kantarjian H; Jabbour E; Gonzalez GN; Borthakur G; Pemmaraju N; Daver N; Gachimova E; Ferrajoli A; Kornblau S; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Sep; 2(9):e376-83. PubMed ID: 26436130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
    Boddu P; Shah AR; Borthakur G; Verstovsek S; Garcia-Manero G; Daver N; Kadia T; Ravandi F; Jain N; Alhuraiji A; Burger J; Kornblau S; Pierce S; Dellasala S; Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2018 Jun; 59(6):1312-1322. PubMed ID: 28972430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
    Boddu P; Jain P; Borthakur G; Verstovsek S; Garcia-Manero G; Daver N; Kadia T; Ravandi F; Jabbour E; Cortes J; Kantarjian H
    Leuk Lymphoma; 2019 Dec; 60(13):3172-3180. PubMed ID: 31125272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
    Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
    Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
    Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
    Haddad FG; Issa GC; Jabbour E; Yilmaz M
    Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
    Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
    Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
    Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
    Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
    Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
    Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Hoy SM
    Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.